TORONTO (Standard&Poor's) Nov. 19, 2013--Standard&Poor's Ratings Services today said that its ratings and outlook on Domtar Corp. (BBB-/Stable/--) are unaffected by the company's announcement that it will be acquiring Spain-based Laboratorios INDAS (not rated). As per the company's announcement, INDAS is valued at about €400 million, which Domtar will acquire through a combination of capital stock purchases and assumption of debt. We expect the transaction to close by year-end. The acquisition will expand Domtar's presence in adult incontinence products in Europe, further diversifying away from the company's core paper and pulp products. The acquisition has no effect on our assessment of Domtar's business risk profile, which remains "fair." We expect earnings from Domtar's personal care segment
